文献速递艾滋病与性传播感染结核与非结核分枝杆菌

双倍剂量洛匹那韦/利托那韦联合利福平或利福布汀治疗HIV-TB合并感染的安全性与药代动力学

Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
PubMed 文献 · Clin Infect Dis · 2021-01-01

研究纳入71例HIV-TB合并感染成人,随机分为LPV/r 400/100 mg每日两次联合利福布汀150 mg/日、LPV/r 800/200 mg每日两次联合利福平600 mg/日、以及LPV/r联合拉替拉韦和利福布汀三组。结果显示双倍剂量LPV/r联合利福平或利福布汀方案安全性、药代动力学及结核结局可接受,但HIV抑制不理想且与药代动力学无关。

要点

  • 双倍剂量LPV/r联合利福平或利福布汀150 mg/日安全性和药代动力学可接受
  • 第48周HIV-1 RNA<400 copies/mL比例在三组分别为58%、67%、61%,HIV抑制不理想
  • 利福布汀联合拉替拉韦组有3例Cmax<250 ng/mL,需进一步研究

核心结论

  • 双倍剂量LPV/r联合利福平及LPV/r联合利福布汀150 mg/日具有可接受的安全性、药代动力学和结核结局,但HIV抑制不理想且与药代动力学无关。

研究设计与样本

  • 2013年7月至2016年2月随机纳入71例HIV-TB合并感染成人,分为A组LPV/r 400/100 mg每日两次+利福布汀150 mg/日、B组LPV/r 800/200 mg每日两次+利福平600 mg/日、C组LPV/r 400/100 mg每日两次+拉替拉韦400 mg每日两次+利福布汀150 mg/日,均联合两种核苷类逆转录酶抑制剂及其他抗结核药。

主要发现

  • 各臂洛匹那韦浓度相似,汇总洛匹那韦AUC12为157 203 hours×ng/mL、Ctrough为9876 ng/mL,与历史对照相似。
  • 利福布汀AUC24为7374 hours×ng/mL、Ctrough为208 ng/mL,较历史对照更高,但C组3例利福布汀Cmax<250 ng/mL。
  • 第48周HIV-1 RNA<400 copies/mL比例在A、B、C组分别为58%、67%、61%。

临床怎么用

  • 双倍剂量LPV/r联合利福平或利福布汀150 mg/日可用于HIV-TB合并感染治疗,但需关注HIV抑制不理想的问题。
  • 利福布汀联合拉替拉韦时利福布汀Cmax偏低,需进一步研究监测。

局限性

  • 样本量较小(71例),HIV抑制不理想的机制未明确,利福布汀联合拉替拉韦的低Cmax需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Protease inhibitor-based antiretroviral therapy may be used in resource-limited settings in persons with human immunodeficiency virus and tuberculosis (HIV-TB). Data on safety, pharmacokinetics/pharmacodynamics (PK/PD), and HIV-TB outcomes for lopinavir/ritonavir (LPV/r) used with rifampin (RIF) or rifabutin (RBT) are limited. METHODS: We randomized adults with HIV-TB from July 2013 to February 2016 to arm A, LPV/r 400 mg/100 mg twice daily + RBT 150 mg/day; arm B, LPV/r 800 mg/200 mg twice daily + RIF 600 mg/day; or arm C, LPV/r 400 mg/100 mg twice daily + raltegravir (RAL) 400 mg twice daily + RBT 150 mg/day. All received two nucleoside reverse transcriptase inhibitors and other TB drugs. PK visits occurred on day 12 ± 2. Within-arm HIV-TB outcomes were summarized using proportions and 95% CIs; PK were compared using Wilcoxon tests. RESULTS: Among 71 participants, 52% were women; 72% Black; 46% Hispanic; median age, 37 years; median CD4+ count, 130 cells/mm3; median HIV-1 RNA, 4.6 log10 copies/mL; 46% had confirmed TB. LPV concentrations were similar across arms. Pooled LPV AUC12 (157 203 hours × ng/mL) and Ctrough (9876 ng/mL) were similar to historical controls; RBT AUC24 (7374 hours × ng/mL) and Ctrough (208 ng/mL) were higher, although 3 participants in arm C had RBT Cmax <250 ng/mL. Proportions with week 48 HIV-1 RNA <400 copies/mL were 58%, 67%, and 61%, respectively, in arms A, B, and C. CONCLUSIONS: Double-dose LPV/r+RIF and LPV/r+RBT 150mg/day had acceptable safety, PK and TB outcomes; HIV suppression was suboptimal but unrelated to PK. Faster RBT clearance and low Cmax in 3 participants on RBT+RAL requires further study.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kendall MA, Lalloo U, Fletcher CV, et al. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clin Infect Dis. 2021. PMID: 34398956. doi:10.1093/cid/ciab097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。